Pharmacovigilance Market size is expected to exceed USD 8 billion by 2024; according to a new research report by Global Market Insights, Inc. Growing number of adverse drug reactions (ADRs) coupled with increasing prevalence of chronic diseases will drive global pharmacovigilance market size. Below a snapshot from today to 2024: To download our infographic, click here. Continue…

Pharmacovigilance activities has long been fundamental to the pharmaceutical companies. As a result, demand for robust compliance systems and experienced talent have raised the cost of maintaining the infrastructure needed to support pharmacovigilance activities so, many companies decide to outsource some of their pharmacovigilance activities in order to improve effectiveness in managing their Pharmacovigilance Systems. For this…

Starting on the 22nd of November 2017, new improvements and changes will affect users of the EudraVigilance system, such as National Competent Authorities, Marketing Authorisation Holders and Sponsors of clinical trials. The European Medicines Agency (EMA) will launch a new and improved version of EudraVigilance with enhanced functionalities for reporting and analysing suspected adverse reactions….

seQure Life Sciences presents the current pharmacovigilance legislation in Europe:

DIA Europe 2018 17 – 19 April – Basel, Switzerland DIA Europe 2018 is more than just a traditional meeting. It’s a chance to learn, engage, and grow as a professional in health care. DIA Europe 2018 is unique in presenting the entire health care value chain ranging from policy and regulations to R&D, marketing and access….

Page 3 of 3 1 2 3

©2017 - seQure - All Right Reserved - Privacy Policy - Cookie Policy